Systematic identification of H274Y compensatory mutations in influenza a virus neuraminidase by high-throughput screening

Journal of Virology

Volumn 87, Issue 2, 2013, Pages 1193-1199

  Wu, Nicholas C ^a,b   Young, Arthur P ^a   Dandekar, Sugandha ^a   Wijersuriya, Hemani ^a   Al Mawsawi, Laith Q ^a   Sun, Ren ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS SIALIDASE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; COMPENSATORY MUTATION; EMBRYO; ENZYME ACTIVITY; ERROR PRONE POLYMERASE CHAIN REACTION; GENE MUTATION; GENE SEQUENCE; GENETIC PROCEDURES; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; MUTATIONAL ANALYSIS; NEURAMINIDASE GENE; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; REPRODUCTIVE FITNESS; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE PROFILING; VALIDATION PROCESS; VIRUS GENE; VIRUS STRAIN;

CALIFORNIA; DRUG RESISTANCE, VIRAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; NEURAMINIDASE; NEW CALEDONIA; SUPPRESSION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE; SWINE INFLUENZA VIRUS;

EID: 84871965903     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01658-12     Document Type: Article

References (43)

1. Taubenberger JK, Kash JC. 2010. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7:440-451.
2. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RAM, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PDJ, Boxrud D, Sambol AR, Abid SH, ST George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. 2009. Antigenic and genetic characteristics of swineorigin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
3. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. 2010. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463:689-692.
4. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, Pinto LH, Lamb RA. 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 105:10967-10972.
5. Cheung C, Rayner JM, Smith GJD, Wang P, Naipospos TSP, Zhang J, Yuen K, Webster RG, Peiris JSM, Guan Y, Chen H. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:1626-1629.
6. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60:1-24.
7. Holmes EC, Ghedin E, Miller N, Taylor J, Bao Y, St George K, Grenfell BT, Salzberg SL, Fraser CM, Lipman DJ, Taubenberger JK. 2005. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol. 3:e300. doi:10.1371/journal.pbio.0030300.
8. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6:e1001005. doi:10.1371/journal. ppat.1001005.
9. Renaud C, Kuypers J, Englund JA. 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J. Clin. Virol. 52:70-78.
10. Lew W, Chen X, Kim CU. 2000. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7:663-672.
11. Wan Po AL, Farndon P, Palmer N. 2009. Maximizing the value of drug stockpiles for pandemic influenza. Emerg. Infect. Dis. 15:1686-1687.
12. Wagner R, Matrosovich M, Klenk H. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12:159-166.
13. Yen H, Liang C, Wu C, Forrest HL, Ferguson A, Choy K, Jones J, Wong DD, Cheung PP, Hsu C, Li OT, Yuen KM, Chan RWY, Poon LLM, Chan MCW, Nicholls JM, Krauss S, Wong C, Guan Y, Webster RG, Webby RJ, Peiris M. 2011. Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. Proc. Natl. Acad. Sci. U. S. A. 108:14264-14269.
14. Ives JAL, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treat-ment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317.
15. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
16. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
17. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, Ostell J, Lipman D. 2008. The influenza virus resource at the National Center for Biotechnology Information. J. Virol. 82:596-601.
18. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro DJ, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, St George K, Taylor J, Lipman DJ, Fraser CM, Taubenberger JK, Salzberg SL. 2005. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437:1162-1166.
19. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, Kawaoka Y. 2012. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J. Virol. 86: 121-127.
20. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. 2011. Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet. 7:e1001301. doi:10.1371/journal.pgen.1001301.
21. Molla A, Kati W, Carrick R, Steffy K, Shi Y, Montgomery D, Gusick N, Stoll VS, Stewart KD, Ng TI, Maring C, Kempf DJ, Kohlbrenner W. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76:5380-5386.
22. Squires RB, Noronha J, Hunt V, García-Sastre A, Macken C, Baumgarth N, Suarez D, Pickett BE, Zhang Y, Larsen CN, Ramsey A, Zhou L, Zaremba S, Kumar S, Deitrich J, Klem E, Scheuermann RH. 2012. Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respi. Viruses 6:404-416. doi:10.1111/j.1750-2659.2011.00331.x.
23. Hwang S, Kim KS, Flano E, Wu T, Tong LM, Park AN, Song MJ, Sanchez DJ, O'Connell RM, Cheng G, Sun R. 2009. Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type i interferon response. Cell Host Microbe 5:166-178.
24. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
25. Szretter KJ, Balish AL, Katz JM. 2006. Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. 3:15G.1.1-15G.1.22.
26. Abramoff MD, Magalhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophotonics Int. 11:36-42.
27. Rameix-Welti M, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.1000103.
28. Abed Y, Pizzorno A, Bouhy X, Boivin G. 2011. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog. 7:e1002431. doi:10.1371/journal.ppat.1002431.
29. Bloom JD, Nayak JS, Baltimore D. 2011. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS One 6:e22201. doi:10 .1371/journal.pone.0022201.
30. Potier M, Mameli L, Bélisle M, Dallaire L, Melanc̃on SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
31. Inoue M, Barkham T, Leo YS, Chan KP, Chow A, Wong CW, Tze Chuen Lee R, Maurer-Stroh S, Lin R, Lin C. 2010. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg. Infect. Dis. 16:1633-1636.
32. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. 2011. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J. Antimicrob. Chemother. 66:466-470.
33. Hamelin M, Baz M, Abed Y, Couture C, Joubert P, Beaulieu E, Bellerose N, Plante M, Mallett C, Schumer G, Kobinger GP, Boivin G. 2010. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wildtype counterpart in mice and ferrets. PLoS Pathog. 6:e1001015. doi:10 .1371/journal.ppat.1001015.
34. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, Kakugawa S, Le MTQ, Yamashita M, Furuta Y, Ozawa M, Kawaoka Y. 2010. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 6:e1001079. doi:10.1371/journal. ppat.1001079.
35. Fowler DM, Araya CL, Fleishman SJ, Kellogg EH, Stephany JJ, Baker D, Fields S. 2010. High-resolution mapping of protein sequence-function relationships. Nat. Methods 7:741-746.
36. Arumugaswami V, Remenyi R, Kanagavel V, Sue EY, Ngoc Ho T, Liu C, Fontanes V, Dasgupta A, Sun R. 2008. High-resolution functional profiling of hepatitis C virus genome. PLoS Pathog. 4:e1000182. doi:10 .1371/journal.ppat.1000182.
37. Christen B, Abeliuk E, Collier JM, Kalogeraki VS, Passarelli B, Coller JA, Fero MJ, McAdams HH, Shapiro L. 2011. The essential genome of a bacterium. Mol. Syst. Biol. 7:528. doi:10.1038/msb.2011.58.
38. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
39. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
40. Beitzel BF, Bakken RR, Smith JM, Schmaljohn CS. 2010. Highresolution functional mapping of the Venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencing. PLoS Pathog. 6:e1001146. doi:10.1371/journal.ppat.1001146.
41. Chica RA, Doucet N, Pelletier JN. 2005. Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr. Opin. Biotechnol. 16:378-384.
42. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. 2008. Crystal structures of oseltamivirresistant influenza virus neuraminidase mutants. Nature 453:1258-1261.
43. Reetz MT, Carballeira JD. 2007. Iterative saturation mutagenesis (ism) for rapid directed evolution of functional enzymes. Nat. Protoc. 2:891-903. High-Throughput Compensatory Mutation Screen January